In 2021, Dr Jianqiang Zhang and co-investigators from Iowa State University received $30,000 from the AASV Foundation to fund the proposal "Generation of antisera against six commercial PRRSV modified live virus vaccines to evaluate their in vitro cross-neutralization against genetically diverse field and laboratory isolates of PRRSV." An interim report and new publication are available.
The goal was to generate antisera against six commercial PRRSV-2 MLV vaccines in experimentally vaccinated pigs and conduct in vitro cross-neutralization assays to determine the neutralizing antibody titers of each vaccine antisera against PRRSV-2 field isolates representing different genetic lineages and sublineages.
The first stage of the research has been published in the special issue of Viruses: Enteric and Respiratory Viruses in Animals 2023: Development, Evaluation, and Clinical Application of PRRSV-2 Vaccine-like Real-Time RT-PCR Assays. Another publication is anticipated after project completion, anticipated in June 2024.
View other AASV Foundation funded research updates at https://www.aasv.org/foundation/research.htm